Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPASALT: Dapagliflozin Mechanism in T2DM and Kidney Function
NCT03152084Phase 4Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in 24-hour Sodium Excretion at Day 4. Started Jul 2017; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03152084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03152084.